A Randomized Dose-Ranging Study of Neuropeptide y in Patients with Posttraumatic Stress Disorder

Abstract

Background: Anxiety and trauma-related disorders are among the most prevalent and disabling medical conditions in the United States, and posttraumatic stress disorder in particular exacts a tremendous public health toll. We examined the tolerability and anxiolytic efficacy of neuropeptide Y administered via an intranasal route in patients with posttraumatic stress disorder. Methods: Twenty-six individuals were randomized in a cross-over, single ascending dose study into 1 of 5 cohorts: 1.4 mg (n = 3), 2.8 mg (n = 6), 4.6 mg (n = 5), 6.8 mg (n = 6), and 9.6 mg (n = 6). Each individual was dosed with neuropeptide Y or placebo on separate treatment days 1 week apart in random order under double..